Literature DB >> 27348270

Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.

Kellie Young1,2, Maria Aguilar3, Robert Gish4, Zobair Younossi5,6, Sammy Saab7, Taft Bhuket3, Benny Liu3, Aijaz Ahmed4, Robert J Wong8.   

Abstract

Receiving Model for End-Stage Liver Disease (MELD) exception status for hepatocellular carcinoma (HCC) improves wait-list survival and probability of liver transplantation (LT). We aim to evaluate etiology-specific disparities in MELD exception, LT wait-list times, and post-LT outcomes among patients with HCC listed for LT. Using United Network for Organ Sharing 2004-2013 data, we evaluated adults (age > 18 years) with HCC secondary to hepatitis C virus (HCV), nonalcoholic steatohepatitis (NASH), alcoholic cirrhosis (EtOH), hepatitis B virus (HBV), combined EtOH/HCV, and combined HBV/HCV. Multivariate regression models evaluated etiology-specific odds of active exception, probability of receiving LT, and post-LT survival. In total, 10,887 HCC patients were listed for LT from 2004 to 2013. Compared with HCV-HCC patients (86.8%), patients with NASH-HCC (67.7%), and EtOH-HCC (64.4%) had a lower proportion with active MELD exception (P < 0.001). On multivariate regression, NASH-HCC and EtOH-HCC patients had significantly lower odds of active MELD exception compared with HCV-HCC (NASH-HCC-odds ratio [OR], 0.73; 95% confidence interval [CI], 0.58-0.93; P = 0.01; EtOH-HCC-OR, 0.72; 95% CI, 0.59-0.89; P = 0.002). Compared with HCV-HCC patients, NASH-HCC (HR, 0.83; 95% CI 0.76-0.90; P < 0.001), EtOH-HCC (HR, 0.88; 95% CI 0.81-0.96; P = 0.002), and EtOH/HCV-HCC (HR, 0.92; 95% CI 0.85-0.99; P = 0.03) were less likely to receive LT if they had active exception. Without active exception, these discrepancies were more significant (NASH-HCC-HR, 0.22; 95% CI, 0.18-0.27; P < 0.001; EtOH-HCC-HR, 0.22; 95% CI, 0.18-0.26; P < 0.001; EtOH/HCV-HCC-HR, 0.26; 95% CI, 0.22-0.32; P < 0.001). In conclusion, among US adults with HCC listed for LT, patients with NASH-HCC, EtOH-HCC, and EtOH/HCV-HCC were significantly less likely to have active MELD exception compared with HCV-HCC, and those without active exception had a lower likelihood of receiving LT. More research is needed to explore why NASH-HCC patients were less likely to have active MELD exception. Liver Transplantation 22 1356-1366 2016 AASLD.
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27348270     DOI: 10.1002/lt.24507

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

1.  Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.

Authors:  Alexander L Nguyen; Haesuk Park; Pauline Nguyen; Edward Sheen; Yoona A Kim; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2018-10-16       Impact factor: 3.199

Review 2.  Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.

Authors:  Naga S Samji; Rajanshu Verma; Sanjaya K Satapathy
Journal:  J Clin Exp Hepatol       Date:  2019-05-16

3.  Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma.

Authors:  Kelley Weinfurtner; Jennifer L Dodge; Francis Y K Yao; Neil Mehta
Journal:  Transplant Direct       Date:  2020-09-17

Review 4.  Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.

Authors:  George Cholankeril; Ronak Patel; Sandeep Khurana; Sanjaya K Satapathy
Journal:  World J Hepatol       Date:  2017-04-18

5.  Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development.

Authors:  Yan Xu; Jichun Han; Jinjin Dong; Xiangcheng Fan; Yuanyuan Cai; Jing Li; Tao Wang; Jia Zhou; Jing Shang
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

6.  Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States.

Authors:  James M Paik; Linda Henry; Leyla De Avila; Elena Younossi; Andrei Racila; Zobair M Younossi
Journal:  Hepatol Commun       Date:  2019-08-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.